T
Thomas Illmer
Researcher at Dresden University of Technology
Publications - 140
Citations - 9361
Thomas Illmer is an academic researcher from Dresden University of Technology. The author has contributed to research in topics: Myeloid leukemia & Transplantation. The author has an hindex of 38, co-authored 120 publications receiving 8308 citations. Previous affiliations of Thomas Illmer include Massachusetts Institute of Technology & Genentech.
Papers
More filters
Journal ArticleDOI
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis
Christian Thiede,Christine Steudel,Brigitte Mohr,Markus Schaich,Ulrike Schäkel,Uwe Platzbecker,Martin Wermke,Martin Bornhäuser,Markus Ritter,Andreas Neubauer,Gerhard Ehninger,Thomas Illmer +11 more
TL;DR: In this paper, the authors analyzed the prevalence and the potential prognostic impact of FLT3 mutations in 979 acute myelogenous leukemia (AML) patients and found that a high mutant/wt ratio in ITD-positive patients appears to have a major impact on the prognostic relevance.
Journal ArticleDOI
Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
Valentin Goede,Kirsten Fischer,Raymonde Busch,Anja Engelke,Barbara Eichhorst,Clemens M. Wendtner,Tatiana Chagorova,Javier de la Serna,Marie-Sarah Dilhuydy,Thomas Illmer,Stephen Opat,Carolyn Owen,Olga Samoylova,Karl-Anton Kreuzer,Stephan Stilgenbauer,Hartmut Döhner,Anton W. Langerak,Matthias Ritgen,Michael Kneba,Elina Asikanius,Kathryn Humphrey,Michael Wenger,Michael Hallek +22 more
TL;DR: Combining an anti-CD20 antibody with chemotherapy improved outcomes in patients with CLL and coexisting conditions, and obinutuzumab was superior to rituximab when each was combined with chlorambucil.
Journal ArticleDOI
Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML).
Christian Thiede,Sina Koch,Eva Creutzig,Christine Steudel,Thomas Illmer,Markus Schaich,Gerhard Ehninger +6 more
TL;DR: It is revealed that patients having only an NPM1 mutation had a significantly better overall and disease-free survival and a lower cumulative incidence of relapse and the analysis of the clinical impact in 4 groups revealed this mutation appears to identify patients with improved response toward treatment.
Journal ArticleDOI
Oral selinexor-dexamethasone for triple-class refractory multiple myeloma
Ajai Chari,Dan T Vogl,Maria Gavriatopoulou,Ajay K. Nooka,Andrew Yee,Carol Ann Huff,Philippe Moreau,David Dingli,Craig E. Cole,S. Lonial,Meletios A. Dimopoulos,A. Keith Stewart,Joshua Richter,Ravi Vij,Sascha Tuchman,Marc S Raab,Katja Weisel,Michel Delforge,Robert F Cornell,David Kaminetzky,James E. Hoffman,Luciano J. Costa,Terri L. Parker,Moshe Yair Levy,Martin Schreder,Nathalie Meuleman,Laurent Frenzel,Mohamad Mohty,Sylvain Choquet,Gary J. Schiller,Raymond L Comenzo,Monika Engelhardt,Thomas Illmer,Philip Vlummens,Chantal Doyen,Thierry Facon,Lionel Karlin,Aurore Perrot,Klaus Podar,Michael Kauffman,Sharon Shacham,Lingling Li,Shijie Tang,Carla Picklesimer,Jean-Richard Saint-Martin,Marsha Crochiere,Hua Chang,Samir Parekh,Yosef Landesman,Jatin Shah,Paul G. Richardson,Sundar Jagannath +51 more
TL;DR: Selinexor-dexamethasone resulted in objective treatment responses in patients with myeloma refractory to currently available therapies.
Journal ArticleDOI
Advanced glycation end product-induced activation of NF-kappaB is suppressed by alpha-lipoic acid in cultured endothelial cells.
Angelika Bierhaus,Shlomit Chevion,Shlomit Chevion,Mordechai Chevion,Marion A. Hofmann,Peter Quehenberger,Thomas Illmer,Thomas Luther,Eduard Berentshtein,Hans J. Tritschler,Martin Müller,P. Wahl,Reinhard Ziegler,Peter P. Nawroth +13 more
TL;DR: It is demonstrated that incubation of cultured bovine aortic endothelial cells with AGE albumin resulted in the impairment of reduced glutathione and ascorbic acid levels, and supplementation of cellular antioxidative defense mechanisms by extracellularly administered α-lipoic acid reduces AGEalbumin-induced endothelial dysfunction in vitro.